Transgene Biotek Ltd (TRABI) — shareholding pattern, promoter holding, financials and share price
About Transgene Biotek Ltd (TRABI)
Transgene Biotek Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as TRABI and on the BSE under scrip code 526139. Its ISIN is INE773D01018.
Incorporated in 1990, Transgene Biotek Ltd is in the business of Research & Development [1]
Transgene Biotek Ltd, founded in 1990, is a pioneering biotechnology company in India, focusing on research and development of vaccines, oncology products, and new drug delivery technologies.
The company has a robust product export portfolio, reaching markets in Africa, Russia, China, Malaysia, and the Philippines.
Listed peers in Healthcare Service Provider: Sharma East India Hosp and Medical Research Ltd, Samsrita Labs Ltd, Tejnaksh Healthcare Ltd, Chennai Meenakshi Multispeciality Hospital Ltd, Nidan Laboratories & Healthcare Ltd, Family Care Hospitals Ltd.
Valuation & Returns
10 Jul 2026At ₹3.08 a share on 10 Jul 2026, Transgene Biotek Ltd (TRABI) was valued at a price-to-earnings ratio of -14.15x against an industry P/E of 61.73x and a price-to-book of 2.78x on a book value of ₹1.11 per share. Solomo computes return on equity of -19.73% and return on capital employed of -2.32% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -14.15x
- Industry P/E
- 61.73x
- P/B
- 2.78x
- EPS (TTM)
- ₹-0.22
- Book value / share
- ₹1.11
- ROE
- -19.73%
- ROCE
- -2.32%
- ROA
- -1.15%
- Debt / equity
- 2.05x
- Dividend yield
- 0%
- EBITDA margin
- -195%
- 52-week range
- ₹1.83 – ₹5.26
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Transgene Biotek Ltd (TRABI) reported revenue of ₹0.21 crore, net profit of ₹-1.65 crore and earnings per share of ₹-0.22. That compares with revenue of ₹0.26 crore and net profit of ₹-0.68 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹0.05 crore and net profit ₹-0.46 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.09 | 0.06 | 0.23 | 0.26 | 0.21 |
| Net profit (₹ cr) | -10.4 | -6.01 | -0.66 | -0.68 | -1.65 |
| EPS (₹) | -1.37 | -0.79 | -0.09 | -0.09 | -0.22 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.10% | 135.81% | 44.34% | 13.04% |
| Profit growth | - | - | - | -3.03% |
| Stock price CAGR | 2% | -7% | -7% | -39% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 23.64% of Transgene Biotek Ltd (TRABI) (unchanged from the previous quarter). Market capitalisation was ₹23 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 2.74%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 23.64% | - | - | - | 76.36% |
| Mar 2026 | 23.64% | - | - | - | 76.36% |
| Dec 2025 | 23.64% | - | - | - | 76.36% |
| Sep 2025 | 23.64% | - | - | - | 76.36% |
| Jun 2025 | 23.64% | - | - | - | 76.36% |
| Mar 2025 | 23.64% | - | - | - | 76.36% |
| Dec 2024 | 23.64% | - | - | - | 76.36% |
| Sep 2024 | 23.64% | - | - | - | 76.36% |